Abuse and Effects of Salvia divinorum in a Sample of Patients Hospitalized for Substance Dependence
- 131 Downloads
The study goal is to document the prevalence of salvia use among patients admitted for detoxification of other illicit drug use and to determine its effect. This cross-sectional study included 47 heavy drug users who were admitted for detoxification of other illicit drug abuse at a psychiatric hospital in Lebanon. The prevalence of salvia use was 66%. The salvia effect started and dissipated rapidly (15 min). No significant difference was found between salvia and non-salvia users in terms of affect, cognition and somaesthesia subscales of the Hallucinogen Rating Scale. Ratings of intensity and volition subscales were higher in non-salvia users than salvia users, while perception score was higher in users. Salvia use was correlated with perceptual alteration and hallucinogenic effects.
KeywordsSalvia Drug Substance Addiction Hallucinogen
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Ansonoff, M. A., Zhang, J., Czyzyk, T., Rothman, R. B., Stewart, J., Xu, H., et al. (2006). Antinociceptive and hypothermic effects of salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice. Journal of Pharmacology and Experimental Therapeutics, 318(2), 641–648.CrossRefGoogle Scholar
- Chavkin, C., Sud, S., Jin, W., Stewart, J., Zjawiony, J. K., Siebert, D. J., et al. (2004). Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: Structural and functional considerations. Journal of Pharmacology and Experimental Therapeutics, 308(3), 1197–1203.CrossRefGoogle Scholar
- Featherstone, R. E., Liang, Y., Saunders, J. A., Tatard-Leitman, V. M., Ehrlichman, R. S., & Siegel, S. J. (2012). Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Neurobiology of Disease, 47(3), 338–346.CrossRefGoogle Scholar
- Ranganathan, M., Schnakenberg, A., Skosnik, P. D., Cohen, B. M., Pittman, B., Sewell, R. A., et al. (2012). Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist salvinorin A in humans. Biological Psychiatry, 72(10), 871–879.CrossRefGoogle Scholar
- Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. The Journal of Clinical Psychiatry, 59(Suppl 20), 22–33 (quiz 4–57).Google Scholar
- Substance Abuse and Mental Health Services Administration, Office of Applied Studies (SAMHSA). (2008). The NSDUH report: Use of specific hallucinogens: 2006. Retreived from http://www.oas.samhsa.gov/2k8/hallucinogens/hallucinogens.htm